These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
368 related articles for article (PubMed ID: 8306343)
21. p53 and ras mutations in Ewing's sarcoma. Radig K; Schneider-Stock R; Röse I; Mittler U; Oda Y; Roessner A Pathol Res Pract; 1998; 194(3):157-62. PubMed ID: 9587933 [TBL] [Abstract][Full Text] [Related]
22. Expression of P53, MDM2 and Ki-67 antigens in soft tissue sarcomas. Szadowska A; Olborski B; Harezga-Bal B; Debiec-Rychter M Pol J Pathol; 1999; 50(1):9-16. PubMed ID: 10412269 [TBL] [Abstract][Full Text] [Related]
23. MDM2 gene amplification in bone and soft-tissue tumors: association with tumor progression in differentiated adipose-tissue tumors. Nakayama T; Toguchida J; Wadayama B; Kanoe H; Kotoura Y; Sasaki MS Int J Cancer; 1995 Oct; 64(5):342-6. PubMed ID: 7591308 [TBL] [Abstract][Full Text] [Related]
24. Chromosome 17 abnormalities and TP53 mutations in adult soft tissue sarcomas. Latres E; Drobnjak M; Pollack D; Oliva MR; Ramos M; Karpeh M; Woodruff JM; Cordon-Cardo C Am J Pathol; 1994 Aug; 145(2):345-55. PubMed ID: 8053493 [TBL] [Abstract][Full Text] [Related]
25. Amplification of a gene encoding a p53-associated protein in human sarcomas. Oliner JD; Kinzler KW; Meltzer PS; George DL; Vogelstein B Nature; 1992 Jul; 358(6381):80-3. PubMed ID: 1614537 [TBL] [Abstract][Full Text] [Related]
26. Molecular and immunohistochemical identification of p53 alterations in bone and soft tissue sarcomas. Mousses S; McAuley L; Bell RS; Kandel R; Andrulis IL Mod Pathol; 1996 Jan; 9(1):1-6. PubMed ID: 8821948 [TBL] [Abstract][Full Text] [Related]
27. Amplification and overexpression of the MDM2 gene in a subset of human malignant gliomas without p53 mutations. Reifenberger G; Liu L; Ichimura K; Schmidt EE; Collins VP Cancer Res; 1993 Jun; 53(12):2736-9. PubMed ID: 8504413 [TBL] [Abstract][Full Text] [Related]
28. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification. Habuchi T; Kinoshita H; Yamada H; Kakehi Y; Ogawa O; Wu WJ; Takahashi R; Sugiyama T; Yoshida O J Natl Cancer Inst; 1994 Sep; 86(17):1331-5. PubMed ID: 8064891 [TBL] [Abstract][Full Text] [Related]
29. Alterations of the p53, Rb and MDM2 genes in osteosarcoma. Miller CW; Aslo A; Won A; Tan M; Lampkin B; Koeffler HP J Cancer Res Clin Oncol; 1996; 122(9):559-65. PubMed ID: 8781571 [TBL] [Abstract][Full Text] [Related]
30. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma. Gorgoulis VG; Zoumpourlis V; Rassidakis GZ; Karameris A; Rassidakis AN; Spandidos DA; Kittas C J Pathol; 1996 Oct; 180(2):129-37. PubMed ID: 8976869 [TBL] [Abstract][Full Text] [Related]
31. Relating genotype and phenotype in breast cancer: an analysis of the prognostic significance of amplification at eight different genes or loci and of p53 mutations. Cuny M; Kramar A; Courjal F; Johannsdottir V; Iacopetta B; Fontaine H; Grenier J; Culine S; Theillet C Cancer Res; 2000 Feb; 60(4):1077-83. PubMed ID: 10706127 [TBL] [Abstract][Full Text] [Related]
32. Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature. Boltze C; Schneider-Stock R; Jäger V; Roessner A Pathol Res Pract; 2001; 197(8):563-8. PubMed ID: 11518050 [TBL] [Abstract][Full Text] [Related]
33. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Lonardo F; Ueda T; Huvos AG; Healey J; Ladanyi M Cancer; 1997 Apr; 79(8):1541-7. PubMed ID: 9118036 [TBL] [Abstract][Full Text] [Related]
34. p53 gene mutations in soft-tissue sarcomas--correlations with p53 immunohistochemistry and DNA ploidy. Schneider-Stock R; Radig K; Oda Y; Mellin W; Rys J; Niezabitowski A; Roessner A J Cancer Res Clin Oncol; 1997; 123(4):211-8. PubMed ID: 9177493 [TBL] [Abstract][Full Text] [Related]
35. MDM2 gene amplification correlates with ring chromosome in soft tissue tumors. Nilbert M; Rydholm A; Willén H; Mitelman F; Mandahl N Genes Chromosomes Cancer; 1994 Apr; 9(4):261-5. PubMed ID: 7519048 [TBL] [Abstract][Full Text] [Related]
37. Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. Toguchida J; Yamaguchi T; Ritchie B; Beauchamp RL; Dayton SH; Herrera GE; Yamamuro T; Kotoura Y; Sasaki MS; Little JB Cancer Res; 1992 Nov; 52(22):6194-9. PubMed ID: 1423262 [TBL] [Abstract][Full Text] [Related]
38. Significance of retinoblastoma and mdm2 gene expression as prognostic markers for soft-tissue sarcoma. Würl P; Meye A; Berger D; Lautenschläger C; Bache M; Holzhausen HJ; Schmidt H; Dralle H; Rath FW; Taubert H Langenbecks Arch Surg; 1998 Mar; 383(1):99-103. PubMed ID: 9627179 [TBL] [Abstract][Full Text] [Related]
39. Lack of MDM2 amplification in human leukaemia. Ridge SA; Dyer M; Greaves MF; Wiedemann LM Br J Haematol; 1994 Feb; 86(2):407-9. PubMed ID: 8199038 [TBL] [Abstract][Full Text] [Related]
40. Mutation of the p53 gene in human soft tissue sarcomas: association with abnormalities of the RB1 gene. Stratton MR; Moss S; Warren W; Patterson H; Clark J; Fisher C; Fletcher CD; Ball A; Thomas M; Gusterson BA Oncogene; 1990 Sep; 5(9):1297-301. PubMed ID: 2216456 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]